Ignite Creation Date:
2024-05-05 @ 12:09 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00252863
Status:
COMPLETED
Last Update Posted:
2009-03-17
First Post:
2005-11-14
Brief Title:
DESOLO - SiT Peri-Launch A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Comparison of Symbicort Single Inhaler Therapy Symbicort Turbuhaler 16045 µg 1 Inhalation bid Plus as Needed and Conventional Best Practice for the Treatment of Persistent Asthma in Adults - a 26-Week Randomised Open-Label Parallel-Group Multicentre Study
Status:
COMPLETED
Status Verified Date:
2009-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether Symbicort dosed according to the Symbicort Maintenance and Reliever Therapy SMART concept is superior to standard asthma treatment according to the local German treatment guidelines
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| DESOLO | None | None | None |